Bio whiz Harvey Berger takes helm at groundbreaking startup Kojin Therapeutics.

Biotech veteran Harvey Berger has been appointed as the CEO of Kojin Therapeutics, a Boston-based startup. Kojin Therapeutics was founded in 2019 and is focused on developing classes of pills that utilize ferroptosis biology to target a range of diseases. Ferroptosis is an iron-dependent form of cell death that has been linked to various illnesses. Kojin Therapeutics is developing a class of pills that induce ferroptosis to kill cancer cells and another class that can block ferroptosis to prevent neurodegenerative diseases. The company has not yet disclosed its lead drug candidates. Berger’s appointment comes after a five-year break from the biotech industry.